Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02497781 · ClinicalTrials.gov registry record · Phase 2
Evaluation of Safety, Pharmacokinetics and Efficacy of Ceftazidime and Avibactam (CAZ-AVI ) Compared With Cefepime in Children From 3 Months to Less Than 18 Years of Age With Complicated Urinary Tract Infections (cUTIs)
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 97
- Enrollment target
NCT02497781 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 97 participants.
The verdict
NCT02497781, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 97 participants
- Enrollment target
Study Summary
This study will assess the safety, tolerability and efficacy of ceftazidime and avibactam (CAZ-AVI )versus cefepime in children from 3 months to less than 18 years old with complicated urinary tract infections.
Interventions
- DRUG Cefepime
- DRUG Ceftazidime -avibactam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 97 participants |
| Start Date | 2015-09-24 |
| Est. Completion | 2017-09-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02497781
The ClinicalTrials.gov registry entry for NCT02497781 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 97 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cefepime is the first listed.
NCT02497781 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02497781 about?
NCT02497781 is a clinical study titled "Evaluation of Safety, Pharmacokinetics and Efficacy of Ceftazidime and Avibactam (CAZ-AVI ) Compared With Cefepime in Children From 3 Months to Less Than 18 Years of Age With Complicated Urinary Tract Infections (cUTIs)". This study will assess the safety, tolerability and efficacy of ceftazidime and avibactam (CAZ-AVI )versus cefepime in children from 3 months to less than 18 years old with complicated urinary tract infections.
What is the current status of trial NCT02497781?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 97 participants. The study started on 2015-09-24. Estimated completion is 2017-09-15.
What interventions are being tested in trial NCT02497781?
The interventions under investigation include: Cefepime (DRUG), Ceftazidime -avibactam (DRUG).
Who is sponsoring clinical trial NCT02497781?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.